App-Quantinova.ai

CLINICAL SIGNIFICANCE OF GALECTIN-3 IN PATIENTS WITH RHEUMATOID ARTHRITIS BEFORE THE APPOINTMENT AND AFTER 12 MONTHS OF TREATMENT WITH BIOLOGICAL DRUGS (PRELIMINARY DATA).

Y. Gorbunova - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

CLINICAL SIGNIFICANCE OF SOLUBLE ST2 IN PATIENTS WITH RHEUMATOID ARTHRITIS BEFORE THE APPOINTMENT AND AFTER 12 MONTHS OF TREATMENT WITH BIOLOGICAL DRUGS (PRELIMINARY DATA).

Y. Gorbunova - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

COMPARATIVE FEATURES AND LONGITUDINAL BEHAVIOUR OF RHEUMATOID ARTHRITIS-ASSOCIATED UIP VERSUS IDIOPATHIC PULMONARY FIBROSIS: A SINGLE CENTRE COHORT STUDY

C. Mazeda - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

Hydroxychloroquine

COMPARATIVE RETINOPATHY RISK OF HIGH- VS LOW-DOSE HYDROXYCHLOROQUINE AMONG 4,677 INCIDENT LONG-TERM USERS: EMULATED TARGET TRIAL ANALYSES

A. Jorge - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic retinopathy

Hydroxychloroquine

CORONAVIRUS INFECTION IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (CASE SERIES).

I. Menshikova - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

DIFFERENCES IN THE CLINICAL SPECTRUM OF HAPLOINSUFFICIENCY OF A20 (HA20) CASES DIAGNOSED DURING ADULTHOOD

S. Amikishiyev - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lymphocytopenia

Hydroxychloroquine

DIFFICULTIES AND MENTAL IMPACT OF THE SARS-CoV- 2 PANDEMIC IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A NATIONWIDE PATIENT ASSOCIATION STUDY

M. Scherlinger - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Post traumatic stress disorder

Hydroxychloroquine

EFFECT OF COLCHICINE THERAPY ON ATHEROSCLEROSIS-RELATED CARDIOVASCULAR OUTCOMES IN PATIENTS WITH CALCIUM PYROPHOSPHATE CRYSTAL DEPOSITION DISEASE

E. Cheremushkina - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Myocardial infarction

Hydroxychloroquine

EFFECT OF THERAPY ON SUBCLINICAL CAROTID ATHEROSCLEROSIS IN PATIENTS WITH CALCIUM PYROPHOSPHATE DEPOSITION DISEASE (PILOT STUDY)

M. Eliseev - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

Hydroxychloroquine

EVEN IN SYSTEMIC LUPUS ERYTHEMATOSUS THAT HAS ACHIEVED SUSTAINED LLDAS, ADDITIONAL ADMINISTRATION OF HYDROXYCHLOROQUINE SHOULD BE CONSIDERED.

R. Wakiya - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

FEATURES OF THE COURSE OF COVID-19 IN ELDERLY PATIENTS WITH IMMUNO-INFLAMMATORY RHEUMATIC DISEASES (PRELIMINARY DATA).

N. Muravyeva - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Chronic obstructive pulmonary disease

Hydroxychloroquine

FREQUENCY AND SEVERITY OF COVID-19 IN PATIENTS WITH VARIOUS RHEUMATIC DISEASES TREATED REGULARLY WITH COLCHICINE OR HYDROXYCHLOROQUINE

M. Oztas - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Familial Mediterranean fever

Hydroxychloroquine

GLUCOCORTICOIDS’ TREATMENT IMPAIRS THE MEDIUM-TERM IMMUNOGENIC RESPONSE TO SARS-CoV-2 mRNA VACCINES IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS.

S. Garcia-Cirera - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

HYDROXYCHLOROQUINE REDUCES THE TITERS OF ANTI-DOMAIN 1 ANTIBODIES OVER TIME IN PATIENTS WITH PERSISTENTLY POSITIVE ANTIPHOSPHOLIPID ANTIBODIES: RESULTS FROM THE APS ACTION CLINICAL DATABASE AND REPOSITORY (“REGISTRY”)

C. Chighizola - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Antiphospholipid syndrome

Hydroxychloroquine

HYDROXYCHLOROQUINE SHORTAGE AND ITS RELATION TO ANXIETY LEVEL AND DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS DURING COVID-19 PANDEMIC

M. H. Abu-Zaid - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Lupus

Hydroxychloroquine

IMMUNOGENICITY AND SAFETY OF COVID-19 VACCINATION IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME

G. M. Verstappen - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Sjogren's syndrome

Hydroxychloroquine

IMPACT OF COVID-19 TREATMENTS ON PERIPHERAL CAPILLARY DENSITY EVALUATED BY NAILFOLD VIDEOCAPILLAROSCOPY

E. Gotelli - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Hydroxychloroquine

IMPACT OF HYDROXYCHLOROQUINE LEVEL ON ECG QTC INTERVAL IN PATIENTS WITH RHEUMATIC SYSTEMIC AUTOIMMUNE DISEASES: A REAL-LIFE STUDY

C. Raya-Santos - European League Against Rheumatism (EULAR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Syncope

Hydroxychloroquine

ANTI-IL-6 THERAPY EFFECT FOR REFRACTORY JOINT AND SKIN INVOLVEMENT IN SYSTEMIC SCLEROSIS: A REAL-WORLD, SINGLE CENTER EXPERIENCE

S. Panopoulos - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Scleroderma

Hydroxychloroquine

ARE ANTIMALARIALS SAFE FOR THE HEART OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS? ANALYSIS OF FACTORS ASSOCIATED WITH THE DEVELOPMENT OF HEART FAILURE IN PATIENTS IN THE SPANISH SOCIETY OF RHEUMATOLOGY LUPUS REGISTRY (RELESSER)

I. Ra-Figueroa - European League Against Rheumatism (EULAR) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Filters

1151 Abstracts